Skip to content

Diagnosis of Renal Osteodystrophy in Patients With Reduced Renal Function

Diagnosis of Renal Osteodystrophy in Patients With Reduced Renal Function Can 18F-PET Replace Bone Histomorphometry

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03716128
Enrollment
40
Registered
2018-10-23
Start date
2018-09-26
Completion date
2027-10-31
Last updated
2025-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Osteodystrophy

Brief summary

The aim of the study is to 1. To describe the bone morphology in patients with reduced renal function and high or low parathyroid hormone (PTH) respectively. 2. To investigate if the non-invasive method 18-Fluoride Positron Emission Tomography (18F-PET) can describe the bone turnover and reflect the bone histomorphologic changes 3. To investigate if non-oxidized PTH reflects bone turnover

Detailed description

Patients with reduced renal function and suspected high turnover or low turnover bone disease are recruited. A bone biopsy and a 18F-PET scan are performed and it is investigated if the 18F-PET can discriminate high turnover from low turnover bone disease

Interventions

DIAGNOSTIC_TEST18F-PET

Bone biopsy and 18F-PET

Sponsors

University of Copenhagen
CollaboratorOTHER
Universiteit Antwerpen
CollaboratorOTHER
Ditte Hansen
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients with reduced renal function: Inclusion Criteria: -≥ 18 years * estimated Glomerular Filtration Rate (eGFR) ≤ 20 ml/min/1,73m2 * PTH \< 150 pg/ml or PTH \> 300 pg/ml

Exclusion criteria

* ongoing malignancy * Allergy towards tetracyclin * Pregnancy Control Group: Inclusion Criteria: -≥ 18 years * eGFR \>= 60 ml/min * under examination for c prostata * Prostatic Specific Antigen (PSA) total \<40 µg/l Exclusion: * Former kidney disease * ionized calcium or PTH outside normal range * Known metabolic bone disease * treatment with anticoagulants * Disturbed thrombosis and hemostasis

Design outcomes

Primary

MeasureTime frameDescription
Can 18F-PET-CT describe bone formation rate?The bone biopsy and 18F-PET will be performed during two month for each participantThe ROC curve for 18F uptake by bone measured as bone plasma clearance (ki) to descriminate between high and low bone turnover measured as bone formation rate
Can non-oxidized PTH describe bone formation rate?Blood sample and bone biopsy will be performed during two month for each participantThe relation between non-oxidized PTH in ng/L and bone turnover in bone biopsy described as bone formation rate

Secondary

MeasureTime frameDescription
Can 18F-PET-CT describe mineral apposition rate?The bone biopsy and 18F-PET will be performed during two month for each participantThe ROC curve for 18F uptake by bone measured as bone plasma clearance (ki) to descriminate between high and low bone turnover measured as mineral apposition rate
Can non-oxidized PTH describe mineral apposition rate?Blood sample and bone biopsy will be performed during two month for each participantThe relation between non-oxidized PTH in ng/L and bone turnover in bone biopsy described as mineral apposition rate

Countries

Denmark

Contacts

Primary ContactDitte Hansen, PhD
ditte.hansen.04@regionh.dk+4538683868

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026